This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2020 Apr 7;172(7):509-510.

doi: 10.7326/L20-0052.

Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome

Derek Leong¹, Peter E Wu¹

Affiliations

PMID: 32252074
DOI: 10.7326/L20-0052

Comment

Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome

Derek Leong et al. Ann Intern Med. 2020.

. 2020 Apr 7;172(7):509-510.

doi: 10.7326/L20-0052.

Authors

Derek Leong¹, Peter E Wu¹

Affiliation

¹ University Health Network, University of Toronto, Toronto, Ontario, Canada (D.L., P.E.W.).

PMID: 32252074
DOI: 10.7326/L20-0052

No abstract available

PubMed Disclaimer

Comment in

Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome.
Moll S. Moll S. Ann Intern Med. 2020 Apr 7;172(7):510. doi: 10.7326/L20-0053. Ann Intern Med. 2020. PMID: 32252075 No abstract available.

Comment on

Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial.
Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Riera-Mestre A, Castro-Salomó A, Cuquet-Pedragosa J, Ortiz-Santamaria V, Mauri-Plana M, Solé C, Cortés-Hernández J. Ordi-Ros J, et al. Ann Intern Med. 2019 Nov 19;171(10):685-694. doi: 10.7326/M19-0291. Epub 2019 Oct 15. Ann Intern Med. 2019. PMID: 31610549 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.